<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03470311</url>
  </required_header>
  <id_info>
    <org_study_id>17-12992</org_study_id>
    <nct_id>NCT03470311</nct_id>
  </id_info>
  <brief_title>Benralizumab in Patients With Inadequate Response to Anti-IL5 Monoclonal Antibody Therapies</brief_title>
  <official_title>Benralizumab in Patients With Inadequate Response to Anti-IL5 Monoclonal Antibody Therapies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>McMaster University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>St. Joseph's Healthcare Hamilton</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>McMaster University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      In severe prednisone-dependent eosinophilic asthma, Benralizumab would suppress airway
      eosinophilia that is not suppressed by either Mepolizumab or Reslizumab and this would be
      associated with greater asthma control
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Benralizumab thus targets 'eosinophil biology', by inhibiting the interleukin (IL-5) receptor
      signalling, and inducing apoptosis in cells with an IL-5receptor. Hence, for patients who
      remain 'uncontrolled' on anti-IL-5 therapy (with detectable eosinophil activity and IL5-Rα+
      cells in the airways), the investigators believe would benefit from a strategy that not only
      reduces eosinophil proliferation/recruitment/maturation, but also depletes cells capable of
      inducing downstream IL-5 signalling.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 2018</start_date>
  <completion_date type="Anticipated">June 2019</completion_date>
  <primary_completion_date type="Anticipated">February 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sputum eosinophil percentage</measure>
    <time_frame>Visit 1 (Week 2) and Visit 10 (Week 38)</time_frame>
    <description>Change in Percentage of sputum eosinophils (%)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Blood eosinophils</measure>
    <time_frame>Visit 1 (Week 2) and Visit 10 (Week 38)</time_frame>
    <description>Blood eosinophil level (x10^9/L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Forced Expired Volume in 1 second (FEV1)(pre and post bronchodilator)</measure>
    <time_frame>Visit 1 (Week 2) and Visit 10 (Week 38)</time_frame>
    <description>FEV1 in litres both pre and post bronchodilator</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ACQ-5 (Asthma Control Questionnaire)</measure>
    <time_frame>Visit 1 (Week 2) and Visit 10 (Week 38)</time_frame>
    <description>Asthma Control Questionnaire score (mean answer of 5 questions on a 7-point scale (0=no impairment, 6= maximum impairment).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fraction of exhaled nitric oxide (FeNO)</measure>
    <time_frame>Visit 1 (Week 2) and Visit 10 (Week 38)</time_frame>
    <description>Exhaled nitric oxide measurement in ppb</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Exacerbations (defined as: ER visit/hospitalization requiring prednisone burst)</measure>
    <time_frame>Visit 1 (Week 2) and Visit 10 (Week 38)</time_frame>
    <description>Worsening requiring increase in oral steroids/prednisone (30mg x 5 days)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sputum and blood ILC2 biology</measure>
    <time_frame>Visit 1 (Week 2) and Visit 10 (Week 38)</time_frame>
    <description>Measurement of ILC2 biological cells in both blood and sputum</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sputum autoimmune responses</measure>
    <time_frame>Visit 1 (Week 2) and Visit 10 (Week 38)</time_frame>
    <description>Measurement of autoimmune markers in sputum: anti-eosinophil peroxidase (EPX) and anti-nuclear antibodies (ANA) - (See last reference PubMed ID: 28751233)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Severe Prednisone Dependent Eosinophilic Asthma</condition>
  <arm_group>
    <arm_group_label>Benralizumab</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Benralizumab 30mg in 1mL subcutaneously</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matched placebo (1mL) to active Benralizumab subcutaneously</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Benralizumab</intervention_name>
    <description>30mg in 1mL pre-filled syringe</description>
    <arm_group_label>Benralizumab</arm_group_label>
    <other_name>MEDI-563</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matched placebo (1mL) in pre-filled syringe</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Informed consent Prior to the beginning of the study, patients must be willing and
             fully capable to provide written informed consent.

          2. Diagnosed prednisone-dependent eosinophilic asthma

          3. Previous treatment with 100 mg mepolizumab administered subcutaneously Q4W or
             reslizumab 3 mg/kg IV Q4W for at least 6 months

          4. Sputum eosinophils &gt;3%

          5. ACQ ≥1.5

          6. Age &gt;18

          7. Male or eligible female subjects:

             To be eligible for entry into the study, females of childbearing potential
             (premenopausal women who are not permanently sterilized by means of hysterectomy,
             bilateral oophorectomy, or bilateral salpingectomy) must commit to consistent and
             correct use of a highly effective method of birth control (true sexual abstinence, a
             vasectomized sexual partner, Implanon, female tubal occlusion, Intrauterine device
             (IUD), Depo provera injections, oral contraceptive pills or Nuvaring) for the duration
             of the trial and for 3 months after the last study drug administration. A serum
             pregnancy test is required of all females at the initial Baseline Visit (Visit 1). In
             addition, a urine pregnancy test will be performed for all females prior to
             enrollment, during each scheduled study visit prior to the injection of
             investigational product, and during the Follow-up Visit.

          8. Male subjects who are sexually active must agree to use a double barrier method of
             contraception (condom with spermicide) from the first dose of study drug and for 3
             months after the last dose of study drug.

        Exclusion Criteria:

          1. Currently receiving another monoclonal antibody

          2. Intolerance, hypersensitivity, insensitivity or neutralizing antibody to Mepolizumab
             and/or Reslizumab

          3. Malignancy within the last 5 years

          4. Any co-morbidity that the investigator believes is a contraindication. This includes
             but is not limited to any respiratory, cardiovascular, gastrointestinal,
             hematological, neurological, immunological, musculoskeletal, renal, infectious,
             neoplastic or inflammatory condition that may place the safety of the subject at risk
             during the duration of the study, influence the results of the study or their
             interpretation, or prevent the patient from completing the entire duration of the
             study.

          5. Current pregnancy or lactation

          6. Current smoker or ex-smoker with a smoking history greater than 20 pack years.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Parameswaran Nair, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>McMaster University and St. Joseph's Healthcare Hamilton</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Melanie Kjarsgaard</last_name>
    <phone>9055221155</phone>
    <phone_ext>33024</phone_ext>
    <email>mkjarsga@stjoes.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Manali Mukherjee</last_name>
    <phone>9055221155</phone>
    <phone_ext>37313</phone_ext>
    <email>mukherj@mcmaster.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Firestone Institute for Respiratory Health, Research - St. Joseph's Healthcare</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8N 4A6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Melanie Kjarsgaard, RRT</last_name>
      <phone>9055221155</phone>
      <phone_ext>33024</phone_ext>
      <email>mkjarsga@stjoes.ca</email>
    </contact>
    <contact_backup>
      <last_name>Manali Mukherjee, PhD</last_name>
      <phone>9055221155</phone>
      <phone_ext>37313</phone_ext>
      <email>mukherj@mcmaster.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Parameswaran Nair, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Paul O'Byrne, MB</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <reference>
    <citation>Mukherjee M, Lim HF, Thomas S, Miller D, Kjarsgaard M, Tan B, Sehmi R, Khalidi N, Nair P. Airway autoimmune responses in severe eosinophilic asthma following low-dose Mepolizumab therapy. Allergy Asthma Clin Immunol. 2017 Jan 6;13:2. doi: 10.1186/s13223-016-0174-5. eCollection 2017.</citation>
    <PMID>28070196</PMID>
  </reference>
  <reference>
    <citation>Smith SG, Chen R, Kjarsgaard M, Huang C, Oliveria JP, O'Byrne PM, Gauvreau GM, Boulet LP, Lemiere C, Martin J, Nair P, Sehmi R. Increased numbers of activated group 2 innate lymphoid cells in the airways of patients with severe asthma and persistent airway eosinophilia. J Allergy Clin Immunol. 2016 Jan;137(1):75-86.e8. doi: 10.1016/j.jaci.2015.05.037. Epub 2015 Jul 17.</citation>
    <PMID>26194544</PMID>
  </reference>
  <reference>
    <citation>Sehmi R, Smith SG, Kjarsgaard M, Radford K, Boulet LP, Lemiere C, Prazma CM, Ortega H, Martin JG, Nair P. Role of local eosinophilopoietic processes in the development of airway eosinophilia in prednisone-dependent severe asthma. Clin Exp Allergy. 2016 Jun;46(6):793-802. doi: 10.1111/cea.12695.</citation>
    <PMID>26685004</PMID>
  </reference>
  <reference>
    <citation>Kolbeck R, Kozhich A, Koike M, Peng L, Andersson CK, Damschroder MM, Reed JL, Woods R, Dall'acqua WW, Stephens GL, Erjefalt JS, Bjermer L, Humbles AA, Gossage D, Wu H, Kiener PA, Spitalny GL, Mackay CR, Molfino NA, Coyle AJ. MEDI-563, a humanized anti-IL-5 receptor alpha mAb with enhanced antibody-dependent cell-mediated cytotoxicity function. J Allergy Clin Immunol. 2010 Jun;125(6):1344-1353.e2. doi: 10.1016/j.jaci.2010.04.004.</citation>
    <PMID>20513525</PMID>
  </reference>
  <reference>
    <citation>Mukherjee M, Aleman Paramo F, Kjarsgaard M, Salter B, Nair G, LaVigne N, Radford K, Sehmi R, Nair P. Weight-adjusted Intravenous Reslizumab in Severe Asthma with Inadequate Response to Fixed-Dose Subcutaneous Mepolizumab. Am J Respir Crit Care Med. 2018 Jan 1;197(1):38-46. doi: 10.1164/rccm.201707-1323OC.</citation>
    <PMID>28915080</PMID>
  </reference>
  <reference>
    <citation>Nair P, Wenzel S, Rabe KF, Bourdin A, Lugogo NL, Kuna P, Barker P, Sproule S, Ponnarambil S, Goldman M; ZONDA Trial Investigators. Oral Glucocorticoid-Sparing Effect of Benralizumab in Severe Asthma. N Engl J Med. 2017 Jun 22;376(25):2448-2458. doi: 10.1056/NEJMoa1703501. Epub 2017 May 22.</citation>
    <PMID>28530840</PMID>
  </reference>
  <reference>
    <citation>Mukherjee M, Bulir DC, Radford K, Kjarsgaard M, Huang CM, Jacobsen EA, Ochkur SI, Catuneanu A, Lamothe-Kipnes H, Mahony J, Lee JJ, Lacy P, Nair PK. Sputum autoantibodies in patients with severe eosinophilic asthma. J Allergy Clin Immunol. 2018 Apr;141(4):1269-1279. doi: 10.1016/j.jaci.2017.06.033. Epub 2017 Jul 24.</citation>
    <PMID>28751233</PMID>
  </reference>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 1, 2018</study_first_submitted>
  <study_first_submitted_qc>March 16, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 19, 2018</study_first_posted>
  <last_update_submitted>March 16, 2018</last_update_submitted>
  <last_update_submitted_qc>March 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 19, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Eosinophils</keyword>
  <keyword>asthma</keyword>
  <keyword>inflammation</keyword>
  <keyword>prednisone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulmonary Eosinophilia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

